Human papillomaviruses (HPVs) are the etiological agents of cervical cancer and other human malignancies. HPVs are classified into high-and low-risk genotypes according to their association with cancer. Host cell transformation by high-risk HPVs relies in part on the ability of the viral E6 protein to induce the degradation of p53. We report the development of a cellular assay that accurately quantifies the p53 degradation activity of E6 in vivo, based on the fusion of p53 to Renilla luciferase (RLuc-p53). This assay was used to measure the p53 degradation activities of E6 proteins from 29 prevalent HPV types and variants of HPV type 16 (HPV16) and HPV33 by determining the amount of E6 expression vector required to reduce by half the levels of RLuc-p53 (50% effective concentration [EC 50 ]). These studies revealed an unexpected variability in the p53 degradation activities of different E6 proteins, even among active types whose EC 50 s span more than 2 log units. Differences in activity were greater between types than between variants and did not correlate with differences in the intracellular localization of E6, with most being predominantly nuclear. Protein and mRNA expression of the 29 E6 proteins was also examined. For 16 high-risk types, spliced transcripts that encode shorter E6*I proteins of variable sizes and abundances were detected. Mutation of the splice donor site in five different E6 proteins increased their p53 degradation activity, suggesting that mRNA splicing can limit the activity of some highrisk E6 types. The quantification of p53 degradation in vivo represents a novel tool to systematically compare the oncogenic potentials of E6 proteins from different HPV types and variants.
H
uman papillomaviruses (HPVs) are epithelium-tropic DNA viruses with over 120 different genotypes currently identified (1) . HPVs are the etiological agents of cervical cancer, the second leading cause of cancer-related death among women worldwide. HPV infection is also associated with other anogenital (vaginal, penile, and anal) and head-and-neck tumors. Some HPVs, such as HPV type 5 (HPV5) and HPV8, predominantly infect the skin and are designated cutaneous types, whereas those infecting mucosa are known as mucosal types. HPVs are classified into low-risk or high-risk types based on their association with human malignancies. While infections by low-risk types can cause benign warts or low-grade lesions, those by high-risk HPVs can lead to the development of high-grade lesions and cancer. Carcinogenesis relies primarily on the expression of two virally encoded oncoproteins, E6 and E7, which act synergistically to immortalize and transform the infected cells, in part through their ability to degrade p53 and Rb, respectively (reviewed in references 36 and 42) . The tumor suppressor p53 plays a critical role in the regulation of the cell cycle and in the maintenance of the host genome integrity, and its gene, TP53, is frequently mutated in human cancers (6, 44) . Hence, it is believed that E6-mediated degradation of p53 represents a crucial step in the development of HPV-associated cancers. In particular, the resulting impairment of the response to genomic stress is thought to favor the emergence of highly transformed cells with an aggressive phenotype (15, 16) . Accordingly, transgenic mice expressing E6 in the skin develop malignant skin tumors, whereas E7 expression induces primarily benign hyperplasia (25, 54, 55) . In addition to its ability to degrade p53, E6 was also shown to target several other proteins, among which is the multidomain proapoptotic protein Bak (14, 30, 51, 64, 65, 69) . This activity is thought to be important to prevent apoptosis of infected cells and to favor the transformation process.
Consistent with their association with cancer, only the E6 proteins from high-risk HPV types promote p53 degradation, whereas low-risk E6 proteins are devoid of this activity (11, 17, 49, 69, 71) . High-risk E6 proteins promote p53 degradation through their interaction with the E3 ubiquitin-ligase E6-associated protein (E6AP) (9, 27, 28, 48, 49, 71) . When in complex with E6, E6AP polyubiquitinates p53 to trigger its degradation through the proteasome pathway. In the absence of E6, E6AP has no influence on the level of p53 (61) . Although several studies have underlined the importance of E6AP in the E6-mediated degradation of p53, recent publications suggest that other E3 ubiquitin-ligases could substitute for E6AP (40, 67) .
Even though several studies have sought to characterize the difference in p53 degradation activity between low-and high-risk E6, the molecular basis for this difference remains somewhat enigmatic. Some studies have indicated that this difference is not due to an inability of low-risk E6 to interact with p53 (11, 17, 34) or E6AP (5) . It has also been suggested that the subcellular localiza-tion of E6 is essential for its p53 degradation activity, based on the observation that high-risk HPV16, -18, and -31 E6 proteins can localize to the nucleus after transfection whereas low-risk HPV6 and -11 E6 proteins are predominantly cytoplasmic (35, 37, 41, 57, 59, 60, 63) , although HPV11 E6 has also been detected in the nucleus (24) . In another study, the expression levels of E6 have been shown to vary between high-and low-risk types (31) . Specifically, high-risk HPV16 E6 was shown to possess a lower steadystate expression level than E6 from the low-risk HPV6 and -11 or the cutaneous HPV5 and -8.
E6 is transcribed together with E7 to yield a polycistronic E6E7 full-length mRNA as well as two alternatively spliced products known as E6*I and E6*II (2, 13, 29, 50, 62) . These spliced transcripts have been detected only for high-risk HPVs, primarily HPV16, -18, and -31, but not for low-risk types (53) . Interestingly, the E6*I protein of HPV18 has been shown to associate with fulllength E6 as well as with E6AP to inhibit the degradation of p53 promoted by full-length E6 (45, 46) , suggesting that one of its functions is to regulate the p53 degradation activity of E6. E6*I has also been found to function independently of full-length E6 to promote the degradation of the cellular proteins Akt, Dlg, and Scribble (46) and to stabilize procaspase 8 (19, 68) .
Only recently have large-scale studies begun to investigate the p53 degradation activities of several E6 types (20, 26) . These studies provided important information as to which E6 types can promote the degradation of p53 in vitro, using in vitro-translated proteins (26) , and in vivo, in transfected cells (20) . However, as these studies were typically performed using a single concentration of E6 protein (26) or expression vector (20), they were not designed to investigate variations in potency among active E6 types.
To provide a quantitative measure of the p53 degradation activities of different E6 in vivo, we developed a cellular assay based on the in-frame fusion of p53 to Renilla luciferase (RLuc-p53). This assay was then used to measure the p53 degradation activities of E6 proteins from 29 prevalent HPV types and variants of HPV16 and -33, by determining the amount of E6 expression vector required to reduce by half the levels of RLuc-p53 (50% effective concentration [EC 50 ] ). These studies revealed that the p53 degradation activity of E6 can vary by as much as 2 log units, even among active types. In addition, the p53 degradation activities of natural variants of HPV16 E6 and HPV33 E6 were measured and found to be relatively similar in comparison to the larger variations measured between HPV types. We further report that these variations in activity are not related to differences in the intracellular localization of E6, as most E6 types were found to be predominantly nuclear. Analysis of mRNA and protein expression for the 26 E6 proteins revealed that 16 high-risk types undergo mRNA splicing to express shorter proteins, known as E6*I. Finally, we report that mutation of the splice donor site in five different E6 types abrogates the expression of E6*I, as anticipated, and increases the p53 degradation activity of the protein, suggesting that mRNA splicing can limit the activity of some E6 types.
MATERIALS AND METHODS

Plasmids and mutagenesis.
The open reading frame (ORF) of p53 was cloned into pRLuc-3ϫFlag (21) to be expressed as a fusion with Renilla luciferase and a triple-Flag epitope. Coding sequences for E6 proteins  from HPV5, -8, -26, -30, -34, -35, -39, -42, -45, -51, -52, -53, -56, -58,  -59, -66, -68, -69, -70, -73, - were amplified from the appropriate viral genomic DNA by PCR. All HPV E6 genes were subsequently cloned between the BamHI and XbaI sites of plasmids pCMV-3Tag-C2 c-Myc (Stratagene), pRLuc-3ϫFlag, and pEYFP-C1 (Clontech). The resulting plasmids express E6 fused at its N terminus to three copies of the Myc epitope, to RLuc-3ϫFlag, and to enhanced yellow fluorescent protein (YFP), respectively. All plasmids were verified by DNA sequencing. Mutations in HPV E6 were introduced by site-directed mutagenesis using the Pfu Turbo Hotstart DNA polymerase (Stratagene) and subsequently confirmed by sequencing. The E6 splice donor site was mutated from AGGT to AGCT for HPV16, as previously done by Vaeteewoottacharn et al. (70) , and to AGAT for HPV31, -56, and -66, as previously done for HPV18 E6 by Cheng et al. (10) . These mutations result in the following amino acid changes in E6: V49L in HPV16 E6, G35D in HPV31 E6, V45I in HPV56 E6, and V21I in HPV66 E6.
Cell culture and transfection. The human cervical carcinoma C33A, the spontaneously transformed skin epithelial HaCaT, and the non-smallcell lung carcinoma H1299 cell lines were grown in Dulbecco modified Eagle medium (DMEM), supplemented with 10% fetal bovine serum, 50 IU of penicillin/ml, 50 g of streptomycin/ml, and 2 mM L-glutamine. Transfections were performed using Lipofectamine 2000 reagent according to the manufacturer's recommendations (Invitrogen).
Antibodies and Western blot analysis. C33A were transfected with the indicated plasmids. Twenty-four hours after transfection, cells lysates were prepared, separated by SDS-PAGE, transferred onto polyvinylidene difluoride membranes, and analyzed by Western blotting. Endogenous p53 was detected using a monoclonal antibody from Invitrogen (catalog no. AHO0152), whereas an anti-Flag M2 antibody from Sigma-Aldrich (catalog no. F1804) was used to detect p53 or E6 fused to the RLuc-3Flag epitope (RLuc-p53 or RLuc-E6). ␤-Tubulin was detected using a mouse monoclonal antibody from Sigma-Aldrich (catalog no. T0426). Horseradish peroxidase-conjugated sheep anti-mouse secondary antibody from GE Healthcare (catalog no. NA931) and an enhanced chemiluminescence detection kit (GE Healthcare) were used to visualize the bound primary antibodies.
Luciferase assays. For p53 degradation assays, the plasmid encoding RLuc-p53 (40 ng per well) was cotransfected with the FLuc normalization plasmid in the absence or in the presence of increasing amounts of HPV E6 plasmids into 3 ϫ 10 4 C33A, H1299, or HaCaT cells in white 96-well plates. Twenty-four hours after transfection, FLuc and RLuc activities were measured using the Dual-Glo luciferase system (Promega) and a GloMax 96-well luminometer (Promega) according to the instructions from the manufacturer (21) . For each transfection, the total amount of transfected DNA was normalized by the addition of the appropriate empty vector. Degradation assays were performed at least three times with at least two independent DNA preparations for each plasmid. To calculate expression slopes of RLuc-E6 proteins, increasing amounts of each RLuc-E6 expression plasmid were cotransfected with a constant amount of FLuc normalization plasmid into C33A cells and the FLuc and RLuc activities measured at 24 h posttransfection, as described above.
Statistical analysis. The GraphPad Prism 5 software was used to calculate means, standard errors of the means (SEMs), EC 50 s, and r 2 goodness-of-fit values as well as to perform two-way analysis of variance (ANOVA) comparisons. EC 50 s were calculated by nonlinear regression of the data to the equation y ϭ bottom ϩ (top Ϫ bottom)/{1 ϩ 10 [(log EC 50 Ϫ log x) ϫ n]}, in which x represents the amount of E6 expression plasmid (ng) and y represents the RLuc/FLuc ratio expressed as a percentage of the ratio obtained in the absence of E6. The top and bottom plateaus of the curve are in the same units as y, and n represents the Hill coefficient. SEMs were calculated from at least 3 independent EC 50 determinations.
Fluorescence confocal microscopy. Approximately 8 ϫ 10 5 C33A cells were seeded on microscope coverslips and later transfected with 1.6 g of YFP-E6 expression vector. At 24 hr posttransfection, cells were fixed with 4% formaldehyde (Mecalab, Canada) and then directly permeabilized with 0.2% Triton X-100. DNA was stained with a solution of TO-PRO-3 (1 M) (Molecular Probes) to delineate cell nuclei. Cells were mounted using Vectashield mounting medium (Vector Laboratories). Images were acquired using a LSM510 confocal laser coupled to an Axiovert 100 M inverted scanning microscope (Zeiss, Toronto, Canada) and analyzed using LSM Image Browser software version 3.2.0.70 (Zeiss).
Reverse transcription-PCR (RT-PCR) analysis. cDNAs were produced from C33A cells transfected with the RLuc-E6 expression plasmids using the Cell-to-cDNA II kit (Applied Biosystems) according to the manufacturer's protocol. Briefly, total RNA was extracted from 100,000 transfected cells using 100 l of lysis buffer, and 7.5 l of this extract was used for reverse transcription with oligo(dT) 18 as a primer. The E6-coding region was then PCR amplified from this cDNA pool using the primer pair 5=-ACGATGGCGACTACAAGGAC-3= and 5=-GGAGGTGTGGGAGGT TTTT-3=. PCR conditions were as suggested by the manufacturer. PCR products were separated on a 2% agarose gel, and the bands correspond ing to E6 spliced products were extracted and sequenced using the primer 5=-ACGATGGCGACTACAAGGAC-3=.
RESULTS
Measurement of p53 expression and degradation using a quantitative luciferase-based assay. In order to monitor p53 protein levels in vivo, we developed a luciferase-based assay in which p53 is expressed in fusion with Renilla luciferase (RLuc) and the associated luciferase activity serves as a measure of p53 expression (Fig.  1A) . First, expression of the RLuc-p53 fusion protein was confirmed by Western blotting (Fig. 1B) . Next, the sensitivity and linearity of this assay were tested by cotransfecting increasing amounts of the plasmid encoding RLuc-p53 and a constant amount of a firefly luciferase (FLuc) expression vector, which was used as an internal control to normalize for transfection efficiency and cell viability (Fig. 1C) . RLuc-p53 expression was calculated as the RLuc/FLuc ratio. As anticipated, the transfection of increasing amounts of RLuc-p53 plasmid resulted in a linear increase in expression (Fig. 1C) . To determine whether this assay is suitable for quantifying the degradation of p53 by HPV E6, RLuc-p53 was coexpressed with HPV11 E6 and HPV16 E6, which are, respectively, inactive and active in promoting p53 degradation ( Fig. 2A) . Increasing the amount of HPV16 E6 resulted in a progressive decrease in p53 expression. In contrast, HPV11 E6 did not alter p53 expression levels, demonstrating the specificity of this assay. As expected, neither HPV11 E6 nor HPV16 E6 inhibited RLuc expression. Importantly, we verified that the decrease in RLuc-p53 luciferase activity brought about by HPV16 E6 was correlated with a reduction in the steady-state level of the fusion protein, as measured by Western blotting (Fig. 2B ). Finally, we tested the effects of two mutations in HPV16 E6 that are known to reduce its p53 degradation activity (Fig. 2C) . Specifically, we determined that the ⌬118-122 deletion and the I128T substitution in HPV16 E6, both of which impair its binding to E6AP (39) , also reduce its ability to promote the degradation of RLuc-p53 in our luciferase assay. As a control, we also tested the effect of the G134V substitution, which impairs the ability of E6 to bind to p300 but has little effect on its p53 degradation activity (39, 66) . As anticipated, the G134V E6 mutant was only slightly less active than wild-type HPV16 E6 in promoting the degradation of p53 (Fig, 2C ). The results from these different luciferase assays were analyzed by nonlinear regression (see Materials and Methods) to determine the amount of expression vector necessary for each E6 to reduce by 50% the expression of p53 (EC 50 ). The EC 50 s calculated for wild-type E6 and for the ⌬118-122, I128T, and G134V mutant derivatives were 0.79, 5.64, 6.04, and 2.91 ng, respectively. Collectively, these results suggest that the RLuc-p53 luciferase assay allows for the quantitative measurement of p53 expression and its degradation by HPV E6.
Determination of the p53 degradation activities of HPV16 and HPV33 E6 natural variants. HPV16 and -33 are high-risk HPVs frequently detected in cervical cancer. Naturally occurring variants of HPV16 and -33 with polymorphisms in the E6 open reading frame (ORF) have been reported (18, 22, 32, 58, 72) , some of which have been linked to oncogenicity (23, 47, 73) . To investigate whether these polymorphisms have an impact on p53 degradation by E6, we performed p53 expression assays in the presence of HPV16 E6 variants R10G, L83V, and R10G/L83V, as well as HPV33 E6 K35N (N), K35N/N86H (NH), I73L/V83L/K93N/ A138V (LLNV), P36T/I73L/V83L/K93N/A138V (TLLNV), and A18V/P36T/I73L/V83L/K93N/A138V (VTLLNV) and the prototype HPV16 E6 and HPV33 E6 (Fig. 3 ). As expected, prototypic and variant forms of HPV16 E6 and HPV33 E6 led to a decrease in p53 expression. Our data demonstrate that all HPV16 E6 variants are slightly more efficient than the prototype in degrading p53, as revealed by their lower EC 50 s (Fig. 3A) . In contrast, among the E6 proteins encoded by HPV33 variants, only VTLLNV possesses a significantly higher p53 degradation activity than the prototype (Fig. 3B ). These results confirm that natural variants of HPV E6 differ in their ability to promote p53 turnover.
Quantitative measurement of p53 degradation by 29 HPV E6 types. To investigate whether p53 degradation activity correlates with HPV prevalence in cervical cancer, p53 expression in the presence of 29 different E6 proteins from HPV types 5, 6, 8, 11, 16, 18, 26, 30, 31, 33, 34, 35, 39, 42, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 70, 73, 82, 83 , and 97 was quantified. Twelve of these genotypes are designated oncogenic (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 , and 59), while 11 are classified as possibly oncogenic (types 26, 30, 34, 53, 66, 68, 69, 70, 73, 82 , and 97) (reviewed in reference 4). Cutaneous types 5 and 8 have been associated with skin cancers in individuals with epidermodysplasia verruciformis. HPV6, -11, and -42 are low-risk genital types. HPV83 has not been classified yet as either a high-or low-risk genotype. The expression of E6 from most HPV genotypes led to a significant decrease in p53 expression (Fig. 4) . In contrast, E6 from HPV5, -6, -8, -11, -42, and -83 did not promote p53 degradation. The EC 50 s, representing the degradation activities of the different E6 proteins, are presented in Table 1 . The EC 50 s varied from 0.03 ng for HPV59 to 6.48 ng for HPV66, spanning more than 2 log units and highlighting an unexpected variability in the p53 degradation activities of high-risk E6 types. Importantly, the determined EC 50 for HPV16 E6 was not significantly lower than those of the other HPV E6 proteins tested. The HPV58 and -59 E6 proteins were the most active types, whereas HPV56 and -66 were the least potent. For the latter two types, we observed that the maximal level of p53 degra- were measured in cells transfected with RLuc or RLuc-p53 expression vector, together with increasing amounts of a second plasmid encoding either HPV11 E6 or HPV16 E6. A constant amount of a third plasmid encoding firefly luciferase (FLuc) was used as an internal control. RLuc-p53 expression levels are reported as RLuc/FLuc ratios. The ratio measured from cells expressing RLuc or RLuc-p53 in the absence of HPV E6 was set at 100%. (B) Western blot demonstrating the degradation of RLuc-p53 by HPV16 E6 but not HPV11 E6. The amounts of HPV16 E6 plasmid used in this experiment are proportional to those used for panel A. The single amount of HPV11 E6 plasmid used as a control is the same as the largest amount of HPV16 E6 plasmid tested. RLucp53 was detected using an anti-Flag antibody. Tubulin was use as a loading control. (C) Effects of known amino acid substitutions in HPV16 E6 on its ability to promote the degradation of RLuc-p53. Increasing amounts of the wild type (WT) or of the indicated mutant HPV16 E6 expression plasmids were tested for their effects on RLuc-p53 expression, as described for panel A. The EC 50 represents the calculated amount of HPV E6 expression vector needed to reduce RLuc-p53 expression by 50%. r 2 values for the calculation of the EC 50 are indicated. dation obtained was significantly lower than 90% (P Ͻ 0.001) ( Table 1) , consistent with their lower activity.
The relative p53 degradation activities of E6 are comparable in various cell lines. To determine if the variability in the p53 degradation activities of different E6 types would also be observed in other cell lines, we measured the p53 degradation activities of E6 from HPV5, -6, -8, -11, -16, -18, -31, -33, -42, -58, -66, and -83 in HaCaT and H1299 cells. HaCaT cells are spontaneously transformed human epithelial cells from the skin, whereas H1299 cells are p53-null cells derived from a non-small-cell lung carcinoma (3, 38) . Our results indicate that the ability of E6 to degrade p53 is independent of the cell line used and of the status of the endogenous p53. Indeed, E6 types that were unable to promote p53 degradation in the C33A cell line, specifically those from HPV5, -6, -11, -42, and -83, were also inactive in HaCaT and H1299 cells (data not shown). Furthermore, the relative efficiencies of E6 proteins in promoting p53 degradation activity were also conserved among the various cell lines tested (Table 2) . Indeed, in all three cell lines, HPV58 E6 was the most efficient type at promoting p53 degradation, whereas HPV66 E6 was consistently the least active. In general, we have found that the luciferase assay performs more robustly in C33A cells than in the other two cell lines, as shown by the correlation coefficient (r 2 ) values of the EC 50 curves, a finding that we attribute to the higher transfection efficiency of C33A cells (data not shown). We also noted that the EC 50 s measured in HaCaT cells tended to be higher, perhaps because expression of E6 is lower in these cells as a result of their poor transfection efficiency. Collectively, these results indicate that the efficiency with which different E6 proteins can degrade p53 is variable not only within C33A cells but also within H1299 and HaCaT cells.
Subcellular localization of HPV E6 proteins. A hypothesis proposed to explain the inability of low-risk E6 to degrade p53 is that these proteins do not localize to the nuclear compartment within infected cells. To determine the subcellular localization of the various HPV E6 proteins used in this study, they were expressed in fusion with the yellow fluorescent protein (YFP) in C33A cells and their localization observed by fluorescence confocal microscopy (Fig. 5) . As a control, we verified for two E6 types (HPV16 and -58) that the fusion of YFP at their N termini did not significantly affect their ability to degrade p53 (data not shown).
Our results indicate that with the exception of HPV6, all of the E6 proteins tested could accumulate in the nuclear compartment, with several types showing both nuclear and cytoplasmic localization within the same cell. The cytoplasmic accumulation of HPV6 E6 has been noted previously (63) and could be due in part to precipitation and/or aggregation of the protein as a result of overexpression. The other two low-risk E6 proteins, from HPV11 and -42, were located both in the cytoplasm and the nucleus (Fig. 5) , although we did noticed some cells in which HPV11 E6 was predominantly cytoplasmic (data not shown). The two cutaneous E6 types, from HPV5 and -8, were also present in the nucleus, with evidence of nuclear and cytoplasmic accumulation in some cells. All of the E6 proteins that actively degrade p53 were predominantly nuclear, as previously reported for the HPV16, -18, and -31 E6 (35, 41, 57) , with some types also showing some accumulation in the cytoplasm, such as the HPV16, -35, and -53 E6. Altogether, these results indicate that most E6 proteins can be detected in the nucleus independently of their ability to degrade p53.
Expression of HPV E6 proteins. The E6 protein from HPV16, the most prevalent high-risk type, was previously shown to be expressed at lower levels than its counterparts from low-risk HPV6 and -11 (31) . To extend these observations, we quantified the steady-state expression levels of the 29 E6 proteins used in this study by fusing them at their N termini to Renilla luciferase ( Fig.  6A and Table 1 ) and also examined their expression by Western blotting (Fig. 6B) . To measure expression by luciferase assays, increasing amounts of the plasmids coding for RLuc-E6 fusion proteins were cotransfected with a plasmid encoding FLuc for normalization, and the expression level of each HPV E6 fusion protein was quantified as the ratio between RLuc and FLuc activities (inset in Fig. 6A ). As expected, transfecting increasing amounts of RLuc-E6 plasmids resulted in a linear increase in expression. Importantly, at 20 ng of plasmids transfected, all the HPV E6 proteins displayed steady-state expression levels at least 1 log unit lower than those obtained with the control plasmid encoding solely the RLuc enzyme (data not shown). These data indicate that these E6 proteins are poorly expressed, most likely because they are rapidly turned over. Nevertheless, significant differences were observed in the steady-state expression levels of the various E6 proteins. To quantify these differences, the expression data for each E6 protein were analyzed by linear regression and the calculated slope used as a measure of E6 expression ( Fig. 6A and Table 1 ). By these criteria, HPV56 E6 had the highest expression, while HPV6, -11, -34, -59, -73, and -83 E6 accumulated at the lowest levels. The expression of the different RLuc-E6 proteins was further characterized by Western blotting using an anti-Flag or an antiRLuc antibody. Similar results were obtained with both antibodies, and only the results generated with the anti-Flag antibody are shown in Fig. 6B . This analysis revealed a significant level of heterogeneity among the different E6. Several E6 types produced predominantly a single band, corresponding in size to the full-length RLuc-E6 protein, with relatively little to no lower-molecularweight products; these types included the three low-risk types (HPV6, -11, and -42), the two cutaneous types (HPV5 and -8), and the ambiguous type HPV83. In contrast, several of the highrisk E6 types expressed significant amounts of shorter proteins, perhaps due to mRNA splicing, which has been shown to occur for HPV16, -18, and -31 E6 (2, 13, 29, 50, 62). Some of these lowermolecular-weight proteins may also be due to protein degradation, as the E6 proteins of high-risk HPVs are very unstable (31; D. Gagnon and J. Archambault, unpublished data). Interestingly, some E6 types, and in particular those from HPV56 and -66, produced large amounts of these shorter proteins, which likely accounts for their higher expression measured in luciferase assays (Fig. 6A) . Collectively, these results indicate that the expression levels of the different E6 proteins do not strictly correlate with their p53 degradation activities. Furthermore, they highlight that expression of the high-risk E6 proteins is heterogeneous, in contrast to that of the low-risk and cutaneous types. As such, they also raise the possibility that many high-risk E6 types are subject to mRNA splicing, a possibility that is addressed below.
Splicing of HPV E6 mRNA. It has been shown previously for HPV16, -18, and -31 that the transcripts encoding E6 and E7 can be alternatively spliced to generate mRNAs encoding smaller E6 proteins known as E6*. These shorter mRNAs are generated from a common splice donor site in the E6 ORF and alternative splice acceptor sites located in or downstream of the E6-coding region. An abundant mRNA, known as E6*I, is generated using the splice donor and acceptor sites within E6 and could possibly be produced from some of our E6 expression plasmids. To determine which of the HPV E6 types were subject to splicing, C33A cells were transfected with all 29 RLuc-E6 expression vectors and the structures of RLuc-E6 mRNAs analyzed by RT-PCR using primers located immediately upstream and downstream of the E6 ORF (Fig. 7A) . A prominent cDNA of smaller size than the unspliced transcript was detected for 16 of the 29 E6 types (HPV16, -18, -26, -30, -31, -33, -34, -35, -39, -51, -56, -66, -68, -69, -70, and -82) (Fig. 7B) . As previously reported, none of the low-risk E6 types (HPV6, -11, and -42) showed evidence of mRNA splicing (Fig.  7B) . Similarly, little to no splicing could be observed for the E6 genes from the ambiguous type HPV83 and from the two betatypes HPV5 and -8 (Fig. 7B) . We also could not detect an abundant spliced product for a subset of high-risk E6 types (HPV45, -52, -53, -58, -59, -73, and -97) despite several attempts and increasing the number of PCR cycles. We then characterized the 16 spliced cDNAs originating from the other high-risk E6 types by DNA sequencing in order to determine the locations of the splice donor and acceptor sites and, importantly, to deduce the amino acid sequences of the encoded E6* proteins. Satisfyingly, the splice sites (Fig. 7C ) and predicted sequences of E6* (Fig. 8 ) that we obtained for HPV16, -18, and -31 E6 were the same as those previously reported (29) , thus validating the use of C33A cells to study the splicing of E6-encoding mRNAs. Interestingly, of the additional 13 E6*I proteins that we identified, several are shorter than those of HPV16, -18, and -31 ( Fig. 8 ) (see Discussion). Collectively, the results presented above indicate that many but not all high-risk E6 types are subject to mRNA splicing to produce E6*I proteins of various sizes. Characterization of splice mutant versions of E6 from selected HPV types. The finding that some high-risk E6 types undergo mRNA splicing and express a mixture of full-length E6 and E6*I raised the possibility that we may have underestimated the ability of the full-length protein to degrade p53, especially given the previous report that E6*I acts as an inhibitor of E6-mediated p53 degradation (45) . This prompted us to evaluate the effect of preventing the synthesis of E6*I on the expression of full-length E6 and on its ability to degrade p53. To do so, we inactivated by mutagenesis the splice donor site (see Materials and Methods) in five E6 types that produce small (HPV16), intermediate (HPV18 and HPV31), and large (HPV56 and HPV66) amounts of E6*I. To ascertain that splicing was indeed abolished by the splice site mutation (SM), RT-PCR was performed on C33A cells transfected 
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with the four RLuc-E6 SM expression vectors and their wild-type counterparts as controls (Fig. 9A) . Mutation of the splice donor site did prevent splicing for all types but, surprisingly, gave rise to a new and different spliced mRNA for both HPV31 and -56. As these new spliced mRNAs were not produced from the wild-type RLuc-E6 expression plasmids, they likely originate from the use of spurious splice sites and were not characterized further. Importantly, analysis of the RLuc-E6 and E6 SM proteins by Western blotting confirmed that the synthesis of E6*I was abolished for all five types (Fig. 9B) . The effect of the SM mutation on E6 and E6*I synthesis was also evident when the expressions of wild-type and SM versions of RLuc-E6 were compared in luciferase assays (Fig.  9C) . The SM mutation decreased the overall expression of HPV18, -31, -56, and -66 RLuc-E6 by 5.50-, 6.85-, 15.70-, and 69.40-fold, respectively, consistent with the synthesis of RLuc-E6*I being abolished. In contrast, the SM mutation only slightly lowered the expression of RLuc-E6 from HPV16 (1.56-fold) (Fig. 9C ), in agreement with the observation by Western blotting that this type expresses lower levels of RLuc-E6*I in C33A cells (Fig. 9B) .
Having verified that the splice site mutation does prevent the synthesis of E6*I, we then tested the ability of the E6 SM mutants to promote the degradation of RLuc-p53 in luciferase assays (Fig.  10) . In all cases, the SM mutation increased the p53 degradation activity of E6 by approximately 3-to 6-fold, as measured by a decrease in EC 50 . Collectively, these results indicate that mRNA splicing can limit the overall capacity of some high-risk E6 to promote the degradation of p53, perhaps because E6*I acts as an inhibitor of this process, as previously suggested (45) . Alternatively, splicing may reduce the levels of p53 degradation by decreasing the synthesis of full-length (i.e., unspliced) E6 mRNA; however, the results from the Western blot shown in Fig. 9C suggest that the levels of full-length E6 are not dramatically increased by mutation of the E6 splice donor site. Finally, these results also suggest that the weak p53 degradation activity of some E6 types, like that of HPV66 E6, is likely an intrinsic property of the protein rather than being caused by expression of E6*I, as the E6 SM mutant retained a low activity (EC 50 ϭ 1.88 ng).
DISCUSSION
In this study, we present a new luciferase-based assay to measure expression p53 and its degradation by HPV E6 proteins. To date, studies on p53 degradation in vivo have been performed mostly through the use of Western blotting and often in response to a unique dose of E6, making it difficult to quantify systematically this activity. Only in vitro studies performed on a few E6 proteins quantitatively measured p53 degradation (49) . The assay described here allows for the facile and quantitative measurement of p53 degradation by E6 in vivo. From a dose-response curve, a unique EC 50 can be determined for each E6 protein that is characteristic of its p53 degradation activity. Using this assay, we determined the p53 degradation activities of 29 different E6 proteins encoded by 27 anogenital and 2 cutaneous HPV types and several naturally occurring HPV16 and -33 E6 variants. Among the anogenital HPV types tested, 24 are classified as definite or potential high-risk types (8, 12) . Our analysis revealed that natural variations in the primary sequences of HPV16 and HPV33 E6 can modestly affect their p53 degradation activity, with the EC 50 s of the variants differing by less than 3-fold from those of the prototypes. Furthermore, our results show that HPV5, -6, -8, -11, -42, and -83 do not promote p53 degradation. Although most of these genotypes were previously found to be innocuous to p53 protein expression (11, 20, 52, 69) , our report is the first to show the inability of HPV83 E6 to degrade p53. HPV83 was originally isolated from a mouse xenograft system, and its association with cancer remains unclear (7). The facts that HPV83 E6 does not promote the degradation of p53 and that it does not contain a C-terminal motif for binding PDZ domain-containing proteins (data not shown) suggest that HPV83 may not be a high-risk type, at least not a typical one, although further characterization of HPV83 will be required to confirm this suggestion. All the other E6 proteins tested, namely, those from HPV16, -18, -26, -30, -31, -33, -34, -35, -39,  -45, -51, -52, -53, -56, -58, -59, -66, -68, -69, -70, -73, -82 , and -97, were able to promote p53 degradation, confirming and extending the results from previous large-scale studies (20, 26) . Importantly, our study provided a measure of the p53 degradation activity for each high-risk E6. In general, we found that differences in p53 degradation activity were greater between HPV types than between natural variants of HPV16 or HPV33 E6 (compare Fig. 3 and Table 1 ). A case in point is the fact that the calculated EC 50 s determined in this study range from 0.03 ng for HPV59 to 6.5 ng for HPV66 ( Table 1 ), indicating that approximately 200-fold more E6 expression vector for HPV66 than for HPV59 E6 is necessary to reduce by half the expression of p53. Even though p53 degradation by E6 proteins from HPV16 and -18 was compared in vitro in a previous study (49) , the differences observed in our experiments were largely unexpected. In addition, our results indicate an absence of a correlation between the efficiency of p53 degradation by E6 and the association of the corresponding HPV genotype with cervical cancer (12, 43) . For example, while HPV16 is the most prevalent HPV in cervical cancer, its E6 protein was not the most efficient at degrading p53 (Table 1) , even when synthesis of E6*I was abolished by mutation of the splice donor site (Fig.  10) . Our findings also show for the first time that although HPV68, -69, and -97 are classified as possibly oncogenic viruses, they encode E6 proteins that are as active in promoting p53 degradation as those from established oncogenic genotypes. Conversely, we found that the E6 proteins from the oncogenic HPV56 and the possibly oncogenic HPV66 were the least active. Collec- tively, these observations do not support the hypothesis that the E6 proteins from the most oncogenic HPV types are the most efficient at degrading p53. The lack of a simple correlation between oncogenicity and p53 degradation could be linked to the ability of E6 to target host proteins other than p53 (42) . Additionally, other viral factors also undoubtedly contribute to oncogenicity, such as the transforming properties of E7 and the strength of the long control region (LCR), which dictates the levels of E6 and E7 expression.
As part of this study, we also examined the intracellular localization of the different E6 types. The calculated molecular mass of E6 is approximately 20 kDa and should allow for the passive diffusion of this small protein through the nuclear pore. However, it was shown that E6 proteins from HPV16, -18, and -31 are predominantly nuclear whereas those from HPV6 and -11 are localized mainly in the cytoplasm (35, 37, 41, 57, 59, 60, 63) , although one study showed that HPV11 E6 could be found in both the nucleus and the cytoplasm (24) . HPV16 E6 was shown to interact in vitro with the karyopherins ␣2, ␤1, and ␤2 (37), suggesting that E6 is actively imported in the nucleus. Our subcellular localization of the 29 HPV E6 proteins used in this study, as fusions with YFP, showed that the E6 proteins from HPV types 11, 16, 18, 26, 30, 31, 33, 34, 35, 39, 42, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 70, 73, 82, 83 , and 97 accumulate predominantly in the nucleus after transfection (Fig. 5) . In contrast, HPV6 E6 was cytoplasmic, perhaps due to precipitation/aggregation of the protein in cytoplasm, as previously observed (37, 63) . Importantly, even though they are unable to trigger the degradation of p53 (Fig. 4) , HPV11, -42, and -83 E6 proteins were detected in the nucleus, indicating that nuclear localization is not sufficient to target p53. A similar argument can be made for the E6 proteins from the two cutaneous types HPV5 and -8, which are found both in the nucleus and in the cytoplasm (Fig.  5) . Interestingly, the nuclear localization sequences RPRKL, KCLKFYSK, and KQRHLDKKQR previously identified in HPV16 E6 (37, 63) are not conserved in HPV5 and -8 E6 and are replaced by LPSTI, V/CCCGATAT, and KLDCCGRGL/RP, respectively. This suggests that other sequences, secondary structures, or interacting partners are responsible for the nuclear localization of E6 proteins from cutaneous HPV types. Alternatively, HPV5 and -8 E6 may enter the nucleus by passive diffusion.
FIG 8
Predicted amino acid sequences of E6‫ء‬I from high-risk HPV types. Predicted amino acid sequences of E6‫ء‬I proteins were aligned using ClustalW2 (33) and shaded using GeneDoc (www.nrbsc.org/gfx/genedoc/). Amino acids that are highly conserved in all E6‫ء‬I proteins or only in a subset of types are highlighted in black and gray, respectively. To test the hypothesis that p53 degradation efficiency is related to the expression of E6, we measured the levels of the 29 HPV E6 proteins through their fusion with RLuc. Our results suggested that HPV56 E6 is the most expressed protein, whereas HPV6, -11, -34, -59, -73, and -83 E6 expression levels are the lowest. However, the results from these luciferase assays must be interpreted cautiously in light of the fact that some of these E6 types undergo mRNA splicing and express a mixture of full-length E6 and E6*I proteins. For example, the high expression of HPV56 E6 in luciferase assays is largely due to the expression of a stable E6*I protein, as mutation of the splice donor site reduced its expression by 15.7-fold (Fig. 9C) . However, for E6 types that do not undergo splicing, the luciferase levels provide an accurate measure of the expression of the full-length protein. For E6 types that do undergo splicing, expression of the full-length protein can be measured using expression plasmids in which the splice donor site has been mutated, as done in Fig. 9C . By comparing the expression slopes of different E6 proteins, we determined that the steady-state levels of the two cutaneous types (HPV5 and -8) were the highest. Compared to the expression of HPV16 E6, using the expression slope determined for the splice mutant version of HPV16 E6 to avoid the confounding effect of E6*I expression, our results confirmed that the HPV5 and -8 E6 proteins are better expressed than fulllength HPV16 E6 (31) . In contrast, our results did not confirm the previous observation that E6 proteins from the two low-risk types HPV6 and -11 are expressed at higher levels than those from HPV5 and -8 (31) . Differences in cell lines and methodologies may account for this difference. We note that in our system, both RLuc-E6 and the FLuc internal control are expressed from an identical cytomegalovirus (CMV) promoter, such that the ratio of their luciferase activities tends to mitigate any effect that E6 may have on transcription from this promoter. When analyzed globally, the results from these expression studies did not support a direct link between E6 expression levels and p53 degradation activity (Table 1) . Nevertheless, the fact that most high-risk E6 proteins were expressed at very low levels suggests that the p53 degradation process is very efficient, at least in C33A cells (Table 2) . Indeed, the amount of HPV59 E6 plasmid needed to reach its EC 50 (0.03 ng) is roughly 1,000-fold lower than the amount of RLucp53 plasmid used in the assay (Table 1) . This is a significant difference given that both E6 and RLuc-p53 are expressed from the same CMV promoter in these experiments. The observation that only a small amount of E6 is sufficient to induce the degradation of p53 in our assay is consistent with the fact that E6 is expressed at low levels from the viral LCR (56) . Although most of the E6 proteins tested could promote the degradation of RLuc-p53 by more than 90% at high concentrations, we found that the HPV56 and -66 E6 proteins were unable to completely deplete p53, presumably because of their lower activity.
Our studies also confirmed that the E6 proteins from HPV16, -18, and -31 are subject to mRNA splicing, while those from the low-risk and cutaneous types are not. Sequencing of the HPV16, -18, and -31 spliced mRNAs (cDNAs) confirmed that they encode a truncated E6 protein known as E6*I. RT-PCR analysis of the other high-risk types revealed that some, but not all, undergo mRNA splicing, and sequencing of these other spliced mRNAs revealed the predicted amino acid sequences of 13 additional E6*I proteins. Interestingly, there are significant differences between the different E6*I proteins, in particular with respect to their sizes and abundances. Indeed, whereas the E6*I proteins of HPV16, -18, -30, -33, -34, -35, -39, -68, and -70 comprise 50 to 55 amino acids, those of HPV26, -31, -51, -56, -66, -69, and -82 are much shorter, ranging in size from 29 to 36 residues. These shorter E6*I proteins lack the first pair of cysteines that coordinate zinc within the N-terminal zinc finger of E6. The E6*I proteins of HPV56 and -66 also lack a conserved hydrophobic motif, ⌽xx⌽x⌽ (where ⌽ is L, I, or M; highlighted in gray in Fig. 8 ). Previous structurefunction studies indicated that a small deletion within this hydrophobic motif of HPV18 E6*I abolishes its ability to bind to fulllength E6 and to E6AP and to inhibit the degradation of p53 promoted by full-length E6 (45a). This raises the possibility that the shorter E6*I proteins of HPV56 and -66, which completely lack this motif, may be unable to inhibit p53 degradation or may employ a different mechanism to do so. We are currently testing this hypothesis. Interestingly, the E6*I proteins of HPV56 and -66 are also the most abundantly expressed, as determined by Western blotting (Fig. 6B and 9B) . It is possible that their small size makes them more stable than the other E6*I proteins and full-length E6.
Our results also support the notion that mRNA splicing does not regulate all high-risk E6 proteins in a similar manner, as we did not detect the synthesis of abundant spliced transcripts for several of them (HPV45, -52, -53, -58, -59, -73, and -97) . The expression pattern of some of these high-risk E6 types, determined by Western blotting, is also consistent with little to no E6*I protein being produced (HPV52, -53, -58, -59, -73, and -83 ). This apparent absence of splicing for some types may be a limitation of the cell lines or expression plasmids that we have used in this study, which, obviously, do not fully recapitulate the expression of E6 from the viral genome in infected keratinocytes. However, we find it interesting that many of the E6 types that are not subject to mRNA splicing in C33A cells are among the most active in promoting the degradation of p53 in these cells. This is exemplified by the HPV58 and -59 E6 proteins, whose EC 50 s are less than 0.1 ng and for which no spliced transcripts were detected.
To begin to investigate the effect of E6 mRNA splicing and E6*I expression in our assay system, we mutated the splice donor site in five E6 types and tested the p53 degradation activities of the resulting mutant proteins. For all five types, the mutant E6 was more active than its wild-type counterpart by 3-to 6.5-fold. This increase in activity is significant and within the range of differences observed between certain E6 types ( Table 1) . At this point, we do not know if the gain in potency achieved by the splice site mutation is due to inhibition of E6*I synthesis or increased expression of full-length E6 from the mutant plasmid. However, we note from the Western blot analysis shown in Fig. 9B that the expression of full-length E6 does not appear to be dramatically upregulated by the splice site mutation. Collectively, these studies provide additional evidence that mRNA splicing can negatively regulate the p53 degradation activity of full-length E6, through direct inhibition of the process by E6*I and/or decreased synthesis of full-length E6 when splicing occurs. In the future, it will be of interest to test whether all of the E6*I proteins reported in this study are able to inhibit the degradation of p53 by full-length E6. The luciferase assay described here is ideally suited for these studies.
